News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

VIVUS, Inc. (VVUS) Diet Pill Patents are Questioned and Stock Sinks


7/20/2012 7:38:42 AM

Shares of Vivus Inc fell sharply on Thursday afternoon after well-known short-seller Citron Research cast doubts on the drugmaker's ability to protect its weight-loss pill's patents.

Citron in a report on its website pointed out the possibility that Johnson & Johnson could challenge Vivus in court over patents that cover usage of anti-seizure drug topiramate -- one of the key ingredients in Vivus' freshly approved Qsymia.

Read at Seeking Alpha
Read at Reuters
Read at Wall Street Journal


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES